ITMCTR2100004818
Recruiting
未知
To investigate the clinical effect and ctDNA dynamic change of 'Jianpi Lishi Huayu Decoction' on the 'maximum androgen blocking' of advanced prostate cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male, in line with the Western medical diagnostic criteria of Diagnostic Criterion for Prostate Cancer, confirmed as prostate cancer by biopsy and puncture, and not complicated with neuroendocrinization, signet ring cell or small cell characteristics;
- •2\. Meet the American Joint Committee on Cancer (AJCC) 8th edition TNM staging criteria for prostate cancer, which are T3\-4, N0\-1, M0\-1;
- •3\. Diagnostic criteria of traditional Chinese medicine: with reference to the teaching material of TCM oncology (dai\-han zhou editor, guangzhou higher education press, 2007\) and the standard of China association of Chinese medicine tumor diagnosis and treatment of traditional Chinese medicine guide (2008\) and the malignant tumor diagnosis and treatment of traditional Chinese medicine guide (hong\-sheng Lin editor, people's medical publishing house, 2014\), the state bureau of technical supervision issued term in the clinical diagnosis and treatment of TCM syndrome part (1997\).
- •4\. No previous endocrine therapy related to prostate cancer;
- •5\. According to Zubrod\-Ecog\-WHO (ZPS, 5\-point method) scoring criteria, the baseline assessment of patients before enrolment should meet 0\-2 points;
- •6\. Bone marrow hematopoietic function was not significantly impaired (WBC \>\= 3\.5 x 10^9/L, platelet \>\= 100 x 10^9/L, hemoglobin \>\= 90g/L);
- •7\. Biochemical examination shall meet the following standards:
- •1\) TBIL \< 1\.5 x ULN;
- •2\) ALT and AST \< 2 ULN (\<\= 5 x ULN if abnormal liver function is caused by liver metastasis);
- •3\) Serum Cr acuities were 1\.25 x ULN or endogenous creatinine clearance \> 45 ml/min (Cockcroft \- Gault formula);
Exclusion Criteria
- •1\. Combined with serious primary diseases of the heart, brain, liver and hematopoietic system or with other cancers;
- •2\. Combined with renal injury due to spinal cord compression or urinary tract obstruction, or who are at risk of developing this phenomenon;
- •3\. Allergic to carlutamine or any component of the preparation;Have a history of allergy to goserrelin acetate/leproterreli;
- •4\. Combined with central nervous system disorders or mental disorders, with a clear history of previous neurological or mental disorders, including epilepsy or dementia;
- •5\. Factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction);
- •6\. Participated in other clinical trials within the last 3 months;n acetate preparation ingredients, synthetic LH\-RH or LH\-RH derivatives;
- •7\. The Investigator believes that there is any condition that may harm the subject or cause the subject to fail to meet or perform the study requirements;
- •8\. Increases the risk of participating in the study or of the study drug and, in the investigator's judgment, may result in a serious disease or non\-tumor comorbidity that would ineligible the patient for inclusion in the study;
- •9\. Failed to comply with the protocol;
- •10\. Unsuitable for inclusion by attending physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
To investigate the clinical effect and ctDNA dynamic change of 'Jianpi-Lishi-Huayu Decoction' on the 'maximum androgen blocking' of advanced prostate cancerITMCTR2100004504The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Recruiting
Not Applicable
Clinical efficacy of ctDNA dynamics before and after total neoadjuvant treatment in locally adjuvant rectal cancer.KCT0008155Chonnam National University Hospital Hwasun Hospital45
Completed
Not Applicable
Prospective study evaluating ctDNA as a biomarker for treatment response in head and neck squamous cell carcinoma*NL-OMON46578Antoni van Leeuwenhoek Ziekenhuis70
Active, not recruiting
Not Applicable
CLINICAL ACTIVITY OF DNA DAMAGING AND NON-DAMAGING CHEMIOTHERAPY REGIMENS IN ADVANCED BREAST CANCER PATIENTS WITH DIFFERENT BIOLOGICAL SUB-TYPES DEFINED BY BIOMARKERS EVALUATION ON CIRCULATING TUMOR CELLS - CTC PLATINUMMETASTATIC BREAST CANCERMedDRA version: 9.1Level: SOCClassification code 10038604EUCTR2009-012738-65-ITAZIENDA USL 4 PRATO
Unknown
Phase 3
Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal CancerRectal Cancer, AdenocarcinomaNeoadjuvant ChemoradiationNCT03038217Peking Union Medical College Hospital300